Panitumumab, Gemcitabine and Carboplatin in Triple-Negative Metastatic Breast Cancer

Phase 2

Completed

• Conditions: Metastatic Breast Cancer
• Interventions: Drug: Panitumumab; Drug: Carboplatin; Drug: Gemcitabine

• Registration Number: NCT00894504
• Lead Sponsor: SCRI Development Innovations, LLC

Brief Summary

In this Phase II trial, the investigators will evaluate the combination of gemcitabine, carboplatin, and panitumumab in the treatment of patients with metastatic triple-negative breast cancer. In addition, to assess the efficacy of this combination, tumor tissue will be examined for the presence of various markers, including K-ras and PI3K-activating mutations, EGFR, PTEN, and p53. Correlation of tumor response with marker expression may define a patient subset that is particularly responsive to treatment with a panitumumab-containing combination.

Detailed Description

All patients will receive a pre-emptive skin care regimen during panitumumab therapy to reduce skin toxicity. Treatment cycles will be repeated every 14 days (2 weeks). During each treatment, panitumumab will be administered first, then carboplatin, then gemcitabine. All drugs will be administered according to standard guidelines. Patients will be re-evaluated for response after completion of 3 cycles (6 weeks) of treatment. Patients with objective response or stable disease will continue treatment. Subsequent re-evaluations will occur every 6 weeks. Patients will continue treatment with all three drugs until tumor progression, or until unacceptable toxicity occurs. If patients experience toxicity caused by gemcitabine/carboplatin and are continuing to benefit from treatment, panitumumab can be continued as a single agent (at the same dose and schedule), at the discretion of the investigator, until disease progression occurs.

Study Timeline

• Study First Submitted: 2009-05-05
• Study First Submitted QC: 2009-05-06
• Study First Posted: 2009-05-07
• Study Start: 2010-02
• Primary Completion: 2014-09
• Study Completion: 2014-09
• Results First Submitted: 2014-11-21
• Results First Submitted QC: 2014-12-09
• Results First Posted: 2014-12-15
• Status Verified: 2015-04
• Last Update Submitted: 2015-04-28
• Last Update Posted: 2015-05-15

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 71

Inclusion Criteria

1. Female patients >=18 years of age.

2. Histologically or cytologically confirmed diagnosis of unresectable locally advanced or stage IV breast cancer.

3. No more than 1 prior treatment regimen for metastatic breast cancer.

4. Estrogen receptor and progesterone receptor negative (defined as <10% staining by IHC).

5. Paraffin-embedded tumor tissue (from the primary tumor or metastasis) for biomarker testing. (In the absence of paraffinembedded tissue, unstained paraffin-embedded tumor slides are acceptable).

6. Measurable disease, as defined by the Response Evaluation Criteria in Solid Tumors (RECIST version 1.1) guidelines

7. HER2 negative tumors. HER2 negativity must be confirmed by one of the following:

   • FISH-negative (FISH ratio <2.2), or
   • IHC 0-1+, or
   • IHC 2-3+ AND FISH-negative (FISH ratio <2.2)

8. Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0-1.

9. Absolute neutrophil count (ANC) >=1.5 × 109/L; platelet count >=100 × 109/L; hemoglobin >=9.0 g/dL.

10. Creatinine <=1.5 mg/dL, or creatinine clearance >=40 mL/min (as calculated by the Cockcroft-Gault method, as follows: Female creatinine clearance = (140 - age) × (weight in kg) × 0.85 (serum creatinine × 72)

11. Adequate hepatic function, defined as follows: total bilirubin <=1.5 x ULN; aspartate aminotransferase (AST) <=3 × ULN (or <= 5 x ULN if liver metastases); alanine aminotransferase (ALT) <=3 x ULN (or <=5 x ULN if liver metastases).

12. Magnesium level >= the institutional lower limit of normal (LLN).

13. Women of childbearing potential must agree to use adequate contraception (per institutional standard of care) during treatment and until 6 months after the last administration of investigational products.

Exclusion Criteria

1. Patients with brain metastases are not eligible.

2. History of another primary cancer, with the exception of the following:

   • Curatively treated in situ cervical cancer;
   • Curatively resected non-melanoma skin cancer;
   • Other primary solid tumor curatively treated with no known active disease present and no treatment administered for >=5 years prior to study enrollment.

3. History of interstitial lung disease (e.g., pneumonitis, pulmonary fibrosis), or any evidence of interstitial lung disease on the CT scan of the chest performed at the baseline visit.

4. Prior anti-EGFR antibody therapy (e.g., cetuximab), or treatment with small-molecule EGFR inhibitors (e.g., gefitinib, erlotinib, lapatinib).

5. Radiotherapy <=14 days prior to study enrollment. Any acute effects of radiotherapy must be resolved prior to the administration of study drugs.

6. Systemic chemotherapy, hormonal therapy, immunotherapy, or experimental or approved proteins/antibodies (e.g., bevacizumab) <=21 days prior to study enrollment.

7. Prior therapy with gemcitabine or carboplatin in the metastatic setting is not permitted. Patients who received gemcitabine or carboplatin as part of adjuvant therapy are eligible, as long as recurrence was first documented >12 months after the last exposure to the drug(s).

8. Major surgery within 28 days or minor surgery within 14 days of study enrollment.

9. Requirement of chronic use of immunosuppressive agents (e.g., methotrexate, cyclosporine).

10. Any investigational agent or therapy <=30 days prior to study enrollment.

11. Uncontrolled or intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia.

12. History of any medical or psychiatric condition or laboratory abnormality that, in the opinion of the investigator, may increase the risks associated with the study participation or administration of the investigational products, or that may interfere with the interpretation of the results.

13. Unwillingness or inability to comply with study requirements.

14. Women who are pregnant or breastfeeding.

15. Patients with known human immunodeficiency virus (HIV), hepatitis C virus, and/or acute or chronic hepatitis B virus infection.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Panitumumab/Gemcitabine/Carboplatin	Panitumumab	Systemic therapy
Panitumumab/Gemcitabine/Carboplatin	Gemcitabine	Systemic therapy
Panitumumab/Gemcitabine/Carboplatin	Carboplatin	Systemic therapy

Primary Outcome Measures

Name	Time	Method
Progression-free Survival (PFS)	every 6 weeks until treatment discontinuation	Measured from Day 1 of study drug administration to disease progression - defined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 as a 20% increase in the sum of the longest diameter of target lesions and/or appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions

Secondary Outcome Measures

Name	Time	Method
Objective Response Rate and Clinical Benefit Rate	every 6 weeks until treatment discontinuation	Estimated as the proportion of subjects who meet the criteria for complete or partial response (CR or PR) per Response Evaluation Criteria in Solid Tumors (RECIST) v 1.1 - for target lesions assessed by MRI: Complete Response (CR) is defined as disappearance of all target lesions; Partial Response (PR) is defined as \>=30% decrease in the sum of the longest diameter of target lesions.
Number of Treatment-related Toxicities Occurring in ≥10% of Patients as a Measure of Tolerability and Toxicity	every 6 weeks until discontinuation of treatment, expected average of 18 months	Assessments made through analysis of treatment-related adverse events and serious adverse events
Correlation of Biomarker Expressions of EGFR, K-ras, p53, PTEN Expression, and PI3K in Triple-negative Breast Cancer With Response to Treatment With the Combination of Gemcitabine, Carboplatin, and Panitumumab	18 months	Median PFS (95% CI), months, reported by biomarker expression/mutation status for: EGFR, p53, PTEN, PIK3CA, KRAS

Trial Locations

Locations (17)

Family Cancer Center; 🇺🇸 Collierville, Tennessee, United States

Los Robles; 🇺🇸 Thousand Oaks, California, United States

Norton Cancer Institute; 🇺🇸 Louisville, Kentucky, United States

Providence Medical Group; 🇺🇸 Terre Haute, Indiana, United States

Florida Cancer Specialists; 🇺🇸 Ft. Myers, Florida, United States

National Capital Clinical Research Consortium; 🇺🇸 Bethesda, Maryland, United States

Center for Cancer and Blood Disorders; 🇺🇸 Bethesda, Maryland, United States

Research Medical Center; 🇺🇸 Kansas, Missouri, United States

Nebraska Methodist Cancer Center; 🇺🇸 Omaha, Nebraska, United States

Atlantic Health System; 🇺🇸 Morristown, New Jersey, United States

Tennessee Oncology; 🇺🇸 Nashville, Tennessee, United States

Aventura Hospital and Medical Center; 🇺🇸 Aventura, Florida, United States

St. Louis Cancer Care; 🇺🇸 Chesterfield, Missouri, United States

Oncology Hematology Care; 🇺🇸 Cincinnati, Ohio, United States

Chattanooga Oncology Hematology Associates; 🇺🇸 Chattanooga, Tennessee, United States

Texas Health Physician Group; 🇺🇸 Dallas, Texas, United States

Peninsula Cancer Institute; 🇺🇸 Newport News, Virginia, United States